Skip to main content

Table 2 Comparison of clinical and molecular features of BRAF mutant cancers stratified by PRDM5 methylation status (n = 214)

From: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups

  PRDM5Methylated PRDM5Unmethylated P value
N BRAF mutant cancers 77/214 (36.0%) 137/214 (64.0%)  
Average Age 72.7 75.0 0.1
Gender (Female) 48/77 (62.3%) 91/137 (66.4%) 0.6
Location (Proximal) 62/72 (86.1%) 102/120 (84.2%) 1.0
AJCC stage I/II 36/65 (55.4%) 74/105 (70.5%) <0.05
AJCC stage III/IV 29/65 (44.6%) 31/105 (29.5%)
Mucinous 9/34 (26.5%) 28/62 (45.2%) 0.08
Differentiation (poor) 15/34 (44.1%) 23/62 (37.1%) 0.5
MSI High 37/77 (48.1%) 83/137 (60.6%) 0.09
CIMP High 59/73 (80.8%) 95/132 (72.0%) 0.2
p53 Mutation 13/39 (33.3%) 15/68 (22.1%) 0.3
Nuclear Beta-Catenin 16/33 (48.5%) 20/59 (33.9%) 0.2
  1. Significant p values indicated in bold text.